{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:06:03Z","timestamp":1793307963633,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.arteri.2026.500892","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:27:18Z","timestamp":1769257638000},"page":"500892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence of elevated lipoprotein(a) levels and associated atherosclerotic cardiovascular diseases in subjects with metabolic disorders: A real-world study in a lipid unit"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2746-8104","authenticated-orcid":false,"given":"Francesco","family":"Di Giacomo Barbagallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosiana","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Ibarretxe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-4954","authenticated-orcid":false,"given":"Lu\u00eds","family":"Masana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2026.500892_bib0145","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis a prospective mendelian randomization study and replication in a case\u2013control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.arteri.2026.500892_bib0150","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.arteri.2026.500892_bib0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.athplu.2024.09.004","article-title":"Lipoprotein(a) and the atherosclerotic burden \u2013 should we wait for clinical trial evidence before taking action?","volume":"58","author":"Fichtner","year":"2024","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.arteri.2026.500892_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.arteri.2026.500892_bib0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2026.500892_bib0170","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.84.10.3224","article-title":"Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen","volume":"84","author":"Eaton","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.arteri.2026.500892_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein (a)\u2013cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2026.500892_bib0180","first-page":"243","article-title":"Consenso sobre lipoprote\u00edna (a) de la Sociedad Espa\u00f1ola de Arteriosclerosis Revisi\u00f3n bibliogr\u00e1fica y recomendaciones para la pr\u00e1ctica cl\u00ednica","volume":"36","author":"Delgado-Lista","year":"2024","journal-title":"Cl\u00edn Invest Arterioscl"},{"key":"10.1016\/j.arteri.2026.500892_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2022.10.004","article-title":"Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"363","author":"Rikhi","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2026.500892_bib0190","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2026.500892_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2017.07.003","article-title":"Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile","volume":"28","author":"Scicali","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.arteri.2026.500892_bib0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pcad.2025.05.008","article-title":"Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience","volume":"92","author":"Bosco","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.arteri.2026.500892_bib0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2024.12.002","article-title":"Evaluations of metabolic and innate immunity profiles in subjects with familial hypercholesterolemia with or without subclinical atherosclerosis","volume":"132","author":"Bosco","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.arteri.2026.500892_bib0210","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-025-02683-y","article-title":"Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation","volume":"24","author":"Di Giacomo Barbagallo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.arteri.2026.500892_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2022.07.001","article-title":"Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels","volume":"50","author":"Rehberger Likozar","year":"2022","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.arteri.2026.500892_bib0220","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacl.2025.02.010","article-title":"Interlaboratory comparison of serum lipoprotein(a) analytical results across clinical assays \u2013 steps toward standardization","volume":"19","author":"Lyle","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2026.500892_bib0225","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2026.500892_bib0230","doi-asserted-by":"crossref","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2026.500892_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a) interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: is there an association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.arteri.2026.500892_bib0240","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy334","article-title":"Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting","volume":"39","author":"Verbeek","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2026.500892_bib0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20186721","article-title":"Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives","volume":"20","author":"Vinci","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.arteri.2026.500892_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106738","article-title":"Lipid lowering combination therapy: from prevention to atherosclerosis plaque treatment","volume":"190","author":"Masana","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.arteri.2026.500892_bib0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2026.500892_bib0260","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1186\/s12967-025-07432-z","article-title":"Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects","volume":"23","author":"Bosco","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.arteri.2026.500892_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2026.500892_bib0270","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500892_bib0275","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2026.500892_bib0280","first-page":"71","article-title":"Influence of triglyceride concentration in lipoprotein(a) as a function of dyslipidemia","volume":"36","author":"Marco-Bened\u00ed","year":"2024","journal-title":"Cl\u00edn Invest Arteriosc (Engl Ed)"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491682600001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491682600001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:35:48Z","timestamp":1788399348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021491682600001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S021491682600001X"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500892","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of elevated lipoprotein(a) levels and associated atherosclerotic cardiovascular diseases in subjects with metabolic disorders: A real-world study in a lipid unit","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500892"}}